PAH

Safety fear halts Keros PAH trial dosing, hitting its shares
Pharmaphorum
Fri, 12/13/24 - 11:32 am
Keros Therapeutics
PAH
cibotercept
clinical trials
Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study
Fierce Pharma
Mon, 11/25/24 - 09:52 am
Merck
Acceleron
Winrevair
sotatercept
PAH
clinical trials
Sandoz, Liquidia score $137M win against United in years-long generic Remodulin dispute
Fierce Pharma
Mon, 09/16/24 - 10:22 pm
Sandoz
United Therapeutics
generics
PAH
Treprostinil
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Reuters
Mon, 05/6/24 - 11:35 am
Gossamer Bio
The Chiesi Group
seralutinib
PAH
pulmonary arterial hypertension
Merck scores key FDA approval for pulmonary arterial hypertension drug Winrevair
Fierce Pharma
Wed, 03/27/24 - 11:22 am
Merck
FDA
PAH
Winrevair
sotatercept
Acceleron
Merck’s next big thing is (probably) on the way
Stat
Tue, 03/26/24 - 11:03 am
Merck
FDA
sotatercept
PAH
J&J Wins FDA Nod for Pulmonary Arterial Hypertension Combo Pill
BioSpace
Mon, 03/25/24 - 11:24 am
JNJ
FDA
PAH
Opsynvi
macitentan
tadalafil
FDA gives Merck priority review for blood vessel disorder therapy sotatercept
Medical Marketing and Media
Thu, 09/28/23 - 11:42 pm
Merck
PAH
sotatercept
FDA
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
BioSpace
Thu, 09/7/23 - 10:49 pm
Alnylam
Roche
PAH
zilebesiran
clinical trials
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Fierce Biotech
Wed, 05/10/23 - 10:10 am
Gossamer Bio
layoffs
seralutinib
Merck
PAH
Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23
Endpoints
Mon, 03/6/23 - 11:15 pm
Merck
PAH
clinical trials
MK-0616
Gossamer's PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure
BioSpace
Tue, 12/6/22 - 08:58 pm
Gosamer Bio
PAH
seralutinib
Gossamer could put pressure on Merck
EP Vantage
Fri, 11/11/22 - 10:26 am
Merck
Gossamer Bio
PAH
sotatercept
United Therapeutics
ralinepag
Sotatercept- the breakthrough PAH has been waiting for?
Clinical Trials Arena
Thu, 11/10/22 - 10:31 am
Merck
sotatercept
Acceleron
PAH
Is Merck Moving Toward Another Blockbuster Drug Launch?
Motley Fool
Wed, 10/26/22 - 10:32 am
Merck
sotatercept
PAH
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Mon, 10/10/22 - 11:06 am
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Long after first nod for inhaled Tyvaso, United Therapeutics scraps PhIII in PH with COPD
Endpoints
Tue, 09/20/22 - 10:32 am
Tyvaso
United Therapeutics
PAH
clinical trials
FDA declines to approve United-MannKind's lung disease therapy
Yahoo/Reuters
Mon, 10/18/21 - 10:42 pm
MannKind
United Therapeutics
Tyvaso
FDA
PAH
Is an Acquisition of Acceleron a Smart Move for Merck?
Motley Fool
Fri, 10/8/21 - 10:35 am
Merck
M&A
Acceleron
PAH
Keytruda
Merck & Co justifies paying up for Acceleron
EP Vantage
Fri, 10/1/21 - 10:46 am
Merck
Accleron
M&A
sotatercept
Reblozyl
PAH

Pages